Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Stock
Key stats
- Market cap
- $7.52B
- Price / Earnings ratio
- 68.1x
- EPS (TTM)
- $1.43
- Volume
- Loading
- 52-week high
- $99.31
- 52-week low
- $37.02
Source: third-party data provider, as of November 13, 2026
Compare with KNSA
Recent news

Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
KNSA

What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
KNSA

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
KNSA

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 59.59
- MACD 12/26/9
- 4.56
- EMA 9 of MACD
- 3.97
- MACD histogram
- 0.59
- SMA 50
- $81.53
- Price above SMA 50
- EMA 50
- $83.10
- Price above EMA 50
- SMA 200
- $62.30
- Price above SMA 200
- EMA 200
- $64.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
KNSA

What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
KNSA

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
KNSA

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
KNSA

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
KNSA

Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
KNSA

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
KNSA

5 Stocks With Recent Price Strength Despite Recent Market Volatility
5 Stocks With Recent Price Strength Despite Recent Market Volatility
KNSA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Sanjiv K. Patel | CEO & Chairman of the Board | 1969 |
| Mr. Mark A. Ragosa C.F.A. | Executive VP & CFO | 1974 |
| Mr. Ross Michael Moat | Executive VP, COO & Principal Operating Officer | 1980 |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Executive VP & Chief Medical Officer | 1965 |
| Mr. Eben Tessari | Consultant | 1982 |
| Mr. Michael R. Megna CPA | Senior VP & Chief Accounting Officer | 1971 |
| Ms. Mei Jang | Senior VP & Chief Technical Officer | — |
| Mr. Jonathan Kirshenbaum | Investor Relations Officer | — |
| Mr. Douglas J. Barry | Senior VP, Chief Legal Officer & Secretary | — |
| Ms. Martina Struck Ph.D. | Senior VP & Chief Regulatory Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 59.59
- MACD 12/26/9
- 4.56
- EMA 9 of MACD
- 3.97
- MACD histogram
- 0.59
- SMA 50
- $81.53
- Price above SMA 50
- EMA 50
- $83.10
- Price above EMA 50
- SMA 200
- $62.30
- Price above SMA 200
- EMA 200
- $64.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $101.00
- Average
- $108.75
- High
- $122.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.8 | +4.2 | ||||||||||
| 2022 | -9.2 | -10.5 | -4.3 | -13.2 | -18.6 | +27.5 | -2.1 | +20.1 | +7.3 | -15.0 | +31.5 | -12.1 |
| 2023 | +0.1 | -11.4 | -14.4 | -2.0 | +26.2 | -0.6 | +35.0 | -8.8 | -2.2 | -9.8 | +6.8 | +4.3 |
| 2024 | -4.9 | +16.1 | -9.2 | -5.0 | -2.0 | -5.3 | +47.8 | +3.8 | -3.9 | -11.3 | -1.8 | -9.5 |
| 2025 | -1.7 | +7.4 | +3.5 | +23.9 | -1.4 | -0.9 | +11.1 | +4.7 | +13.3 | -4.2 | +13.5 | +0.8 |
| 2026 | +4.5 | -0.4 | +4.7 | +11.7 | -12.5 | +32.0 | +18.2 | +7.1 | -5.9 | +22.6 | +5.5 |



